Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment

被引:0
|
作者
Drobyski, WR
Majewski, D
Ozker, K
Hanson, G
机构
[1] Med Coll Wisconsin, Bone Marrow Transplant Program, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA
[4] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
来源
JOURNAL OF IMMUNOLOGY | 1998年 / 161卷 / 05期
关键词
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The purpose of this study was to determine whether ex vivo anti-CD3 Ab-activated T cells behaved in a biologically similar manner as naive T cells with respect to causing graft-vs-host disease (GVHD) and facilitating engraftment after allogeneic marrow transplantation, This question was addressed using two well-defined MHC-incompatible murine models of GVHD (C57BL/6 (H-2(b))-->B10.BR (H-2(k))) and engraftment (C57BL/6 (H-2(b))-->AKR/J (H-2(k))). Transplantation with anti-CD3-activated T cells significantly reduced GVHD compared with that in animals transplanted with equivalent numbers of naive T cells. Protection from GVHD was not T cell subset dependent, as highly enriched populations of either activated CD4(+) or CD8(+) T cells caused less lethal GVHD than comparable numbers of purified naive CD4(+) or CD8(+) T cells. Transplantation with activated T cells also resulted in protection from LPS-mediated GVH lethality in unirradiated F-1 recipients. Analysis of immune recovery indicated that animals transplanted with activated T cells had thymic and splenic B cell reconstitution that compared favorably to that in non-GVHD control mice. When engraftment was analyzed, equivalent degrees of donor cell engraftment were observed when animals were transplanted with limiting numbers (5 x 10(5)) of naive vs activated B6 T cells. Further studies indicated that activated CD8(+) T cells were exclusively responsible for enhancing engraftment and that facilitation of engraftment was dependent upon the direct recognition of host MHC alloantigens. Collectively, these data demonstrate that transplantation,vith anti-CD3 Ab-activated T cells results in a reduction in GVHD, but these cells retain their ability to facilitate alloengraftment. The use of this approach in allogeneic marrow transplantation may represent an alternative strategy to mitigate GVHD without compromising engraftment.
引用
收藏
页码:2610 / 2619
页数:10
相关论文
共 50 条
  • [21] Ex vivo expanded human CD4+CD25+Foxp3+regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD)
    Cao, Tinghua
    Soto, Allis
    Zhou, Wei
    Wang, Weihong
    Eck, Steven
    Walker, Mindi
    Harriman, Gregory
    Li, Li
    CELLULAR IMMUNOLOGY, 2009, 258 (01) : 65 - 71
  • [22] A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
    Carpenter, PA
    Appelbaum, FR
    Corey, L
    Deeg, HJ
    Doney, K
    Gooley, T
    Krueger, J
    Martin, P
    Pavlovic, S
    Sanders, J
    Slattery, J
    Levitt, D
    Storb, R
    Woolfrey, A
    Anasetti, C
    BLOOD, 2002, 99 (08) : 2712 - 2719
  • [23] Anti-CD3 Antibody Ameliorates Transfusion-Associated Graft-Versus-Host Disease in a Chemotherapy-Based Mouse Model With Busulfan and Fludarabine
    Li, Xiaofan
    Song, Qingxiao
    Hu, Wanyu
    Wan, Bo
    Huang, Qinghua
    Li, Qing
    BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY, 2017, 60
  • [24] A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease
    Carpenter, PA
    Lowder, J
    Johnston, L
    Frangoul, H
    Khoury, H
    Parker, P
    Jerome, KR
    McCune, JS
    Storer, B
    Martin, P
    Appelbaum, F
    Abonour, R
    Westervelt, P
    Anasetti, C
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (06) : 465 - 471
  • [25] IN-VIVO OR IN-VITRO ANTI-CD3-EPSILON CHAIN MONOCLONAL-ANTIBODY THERAPY FOR THE PREVENTION OF LETHAL MURINE GRAFT-VERSUS-HOST DISEASE ACROSS THE MAJOR HISTOCOMPATIBILITY BARRIER IN MICE
    BLAZAR, BR
    TAYLOR, PA
    VALLERA, DA
    JOURNAL OF IMMUNOLOGY, 1994, 152 (07): : 3665 - 3674
  • [26] Third Party Invariant Natural Killer T Cells Protect from Lethal Graft-Versus-Host Disease through Donor CD4+CD25+FoxP3+Regulatory T Cells
    Schneidawind, Dominik
    Pierini, Antonio
    Baker, Jeanette
    Buechele, Corina
    Luong, Richard
    Meyer, Everett
    Negrin, Robert
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S60 - S60
  • [27] Pretreatment with Anti-CD3 Monoclonal Antibody Depletes Recipient CCR7+ Dendritic Cells and Prevents Graft-Versus-Host Disease While Preserving GVL Effects
    Liu, Can
    He, Wei
    Li, Xiaofan
    Johnston, Heather F.
    Wang, Miao
    Racine, Jeremy
    Martin, Paul J.
    Forman, Stephen
    Zeng, Defu
    BLOOD, 2011, 118 (21) : 1720 - 1720
  • [28] Donor Allospecific CD44high Centra Memory T Cells Have Decreased Ability to Mediate Graft-vs.-Host Disease
    Huang, Wei
    Mo, Wenjian
    Jiang, Jieling
    Chao, Nelson J.
    Chen, Benny J.
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [29] Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity
    Zhang, Y
    Joe, G
    Zhu, J
    Carroll, R
    Levine, B
    Hexner, E
    June, C
    Emerson, SG
    BLOOD, 2004, 103 (10) : 3970 - 3978
  • [30] Chronic graft-versus-host disease correlates with reduced frequency of FOXP3+CD4+CD25+regulatory T cells
    Zorn, E
    Kim, HT
    Lee, SJ
    Floyd, BH
    Litsa, D
    Arumugarajah, S
    Bellucci, R
    Antin, JH
    Soiffer, RJ
    Ritz, J
    EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) : 47 - 48